- 全部删除
- 您的购物车当前为空
Abeprazan (DWP14012) is a potassium-competitive acid blocker and it is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases[1]. Abeprazan inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required.
Abeprazan (DWP14012) is a potassium-competitive acid blocker and it is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases[1]. Abeprazan inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 1,610 | 5日内发货 | |
5 mg | ¥ 3,960 | 5日内发货 | |
10 mg | ¥ 6,750 | 5日内发货 | |
25 mg | ¥ 9,700 | 5日内发货 | |
50 mg | ¥ 13,800 | 5日内发货 | |
100 mg | ¥ 17,500 | 5日内发货 | |
1 mL x 10 mM (in DMSO) | ¥ 4,450 | 5日内发货 |
产品描述 | Abeprazan (DWP14012) is a potassium-competitive acid blocker and it is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases[1]. Abeprazan inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. |
体外活性 | The mechanism of action of Abeprazan is reversibly binding to H+, K+‐ATPase. It unlike that of PPIs, does not require acidic environment for drug activation[1]. |
体内活性 | In various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models[1], DWP14012 inhibited acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion was equal to or greater than that of vonoprazan, a previously approved P-CAB. |
别名 | DWP14012 |
分子量 | 410.41 |
分子式 | C19H17F3N2O3S |
CAS No. | 1902954-60-2 |
密度 | 1.35 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容